Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to halt rare heart disease progression

NCT ID NCT07306949

Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a medication called acoramidis in 200 people with a rare heart condition called transthyretin cardiac amyloidosis. The goal is to see if the drug can slow down the disease and prevent worsening of heart function. Participants either are newly diagnosed or switch from another similar drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Treatment history of ATTR-CM is one of the following: * Naive participants: newly diagnosed with ATTR-CM and no prior treatment with drugs for ATTR-CM * Switch participants: Participants who are using tafamidis, a TTR stabilizer, as treatment for ATTR-CM and who, in the judgment of the post-marketing clinical trial investigator (co-principal investigator), can be expected to benefit from switching to acoramidis. * Naive participants must meet the following requirements: 1. History of hospitalization for heart failure or heart failure symptoms requiring treatment, including diuretics 2. Echocardiographic end-diastolic ventricular septal thickness greater than 12 millimeters (mm) 3. Confirmed diagnosis of ATTR-CM (wild type or mutant) by one of the following diagnostic methods 1. Tissue biopsy shows amyloid deposition and TTR precursor protein is identified by immunohistochemistry or mass spectrometry. 2. Bone scintigraphy showing strong accumulation \*\* (Perugini score ≥ 2) consistent with myocardium and no M protein, negating the possibility of AL amyloidosis Exclusion Criteria: * Have confirmed diagnosis of AL amyloidosis * Switch participants: prior treatment with gene silencing agents (pachysilane sodium, butrisilane sodium) as treatment for ATTR-CM (including when specifically scheduled to start treatment with a gene silencing agent) * Likelihood of receiving a heart transplant within 1 year from the time screening begins * Hypersensitivity to acoramidis, its metabolites, or additives in the formulation has been confirmed. * Pregnant or lactating women * Has a clinically significant medical condition, an abnormal laboratory test result, or a condition that may jeopardize the safety of the study participant, increase the risk of participation in the post-marketing clinical trial, or affect the study * Participating in an interventional study other than this study, including a clinical trial * In the opinion of the responsible (sub)physician for the post-marketing clinical trial, has a history of drug abuse, alcoholism, or psychiatric disorder that would preclude compliance with this Post-Marketing Clinical Study Protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Transthyretin-type cardiac amyloidosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Transthyretin-type cardiac amyloidosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    16 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Research Site

    NOT_YET_RECRUITING

    Bunkyō City, 113-8431, Japan

  • Research Site

    NOT_YET_RECRUITING

    Bunkyō City, 113-8603, Japan

  • Research Site

    NOT_YET_RECRUITING

    Kumamoto, 860-8556, Japan

  • Research Site

    RECRUITING

    Kurume-shi, 830-0011, Japan

  • Research Site

    NOT_YET_RECRUITING

    Kyoto, 606-8507, Japan

  • Research Site

    NOT_YET_RECRUITING

    Mitaka-shi, 181-8611, Japan

  • Research Site

    NOT_YET_RECRUITING

    Nagoya, 466-8560, Japan

  • Research Site

    NOT_YET_RECRUITING

    Nankoku-shi, 783-8505, Japan

  • Research Site

    NOT_YET_RECRUITING

    Okayama, 700-8558, Japan

  • Research Site

    NOT_YET_RECRUITING

    Ōtsu, 520-2192, Japan

  • Research Site

    NOT_YET_RECRUITING

    Sagamihara-shi, 252-0375, Japan

  • Research Site

    NOT_YET_RECRUITING

    Sapporo, 060-8543, Japan

  • Research Site

    NOT_YET_RECRUITING

    Shinjuku-ku, 160-8582, Japan

  • Research Site

    NOT_YET_RECRUITING

    Suita-shi, 564-8565, Japan

  • Research Site

    NOT_YET_RECRUITING

    Tsu, 514-8507, Japan

  • Research Site

    RECRUITING

    Yufu-shi, 879-5593, Japan